{"id":464937,"date":"2021-03-25T07:33:13","date_gmt":"2021-03-25T11:33:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464937"},"modified":"2021-03-25T07:33:13","modified_gmt":"2021-03-25T11:33:13","slug":"solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/","title":{"rendered":"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled \u201cThe more we learn the less we know about DMD\u2014From micro-dystrophin, to morpholinos, and small molecules\u201d will be held on Thursday, April 1, 2021 from 9:00 a.m.\u00a0– 9:50 a.m. Eastern Time.<\/p>\n

A live webcast of the presentation will be available on the Company\u2019s investor relations website, under the Events page accessible here: https:\/\/investors.solidbio.com\/news-and-events\/events<\/a>. A replay will be available on the Company’s website following the event.<\/p>\n

\n About Solid Biosciences
<\/strong>Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive \u2013 work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com<\/a>.<\/p>\n

\n Investor Contact:<\/strong>
\n
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled \u201cThe more we learn the less we know about DMD\u2014From micro-dystrophin, to morpholinos, and small molecules\u201d will be held on Thursday, April 1, 2021 from 9:00 a.m.\u00a0– 9:50 a.m. Eastern Time. A live webcast of the presentation will be available on the Company\u2019s investor relations website, under the Events page accessible here: https:\/\/investors.solidbio.com\/news-and-events\/events. A replay will be available on the Company’s website following … <\/p>\n

Continue reading “Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464937","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSolid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled \u201cThe more we learn the less we know about DMD\u2014From micro-dystrophin, to morpholinos, and small molecules\u201d will be held on Thursday, April 1, 2021 from 9:00 a.m.\u00a0– 9:50 a.m. Eastern Time. A live webcast of the presentation will be available on the Company\u2019s investor relations website, under the Events page accessible here: https:\/\/investors.solidbio.com\/news-and-events\/events. A replay will be available on the Company’s website following … Continue reading "Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-25T11:33:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day\",\"datePublished\":\"2021-03-25T11:33:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/\"},\"wordCount\":234,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/\",\"name\":\"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=\",\"datePublished\":\"2021-03-25T11:33:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/","og_locale":"en_US","og_type":"article","og_title":"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day - Market Newsdesk","og_description":"CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled \u201cThe more we learn the less we know about DMD\u2014From micro-dystrophin, to morpholinos, and small molecules\u201d will be held on Thursday, April 1, 2021 from 9:00 a.m.\u00a0– 9:50 a.m. Eastern Time. A live webcast of the presentation will be available on the Company\u2019s investor relations website, under the Events page accessible here: https:\/\/investors.solidbio.com\/news-and-events\/events. A replay will be available on the Company’s website following … Continue reading \"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-25T11:33:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day","datePublished":"2021-03-25T11:33:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/"},"wordCount":234,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/","name":"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=","datePublished":"2021-03-25T11:33:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjE1NSM0MDkwMzUxIzIwOTExOTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-to-participate-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-day\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464937"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464937\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}